You had mentioned Cambridge not being a part of the valor study.. From the info on the CDC website there are only two vosaroxin studies, the main one having 124 sites including Cambridge and the other one dealing with MDS and having one site in Texas. Where did you get your info from re: Cambridge?
Thanks jjgiablue for the update analyst comments regarding MDS.. I am assuming this was referring to Myelodysplastic syndrome which is at least common than AML and tends to have a much longer lifespan.
New Leerink analyst comments
The LI-1 Trial has a “pick a winner” design that evaluates several candidates in front-line (FL) AML and could significantly de-risk vosaroxin potential in this setting. The trial is designed to identify promising FL AML candidates that may at least double complete remission (CR) or 12-month survival vs. low dose Ara- C (LDAC) SOC. Baseline expectations for LDAC should be ~15-20% for CRs and 18-20% for 12-
month survival. Advancing from Stage-1 to Stage-2 of this trial would imply a candidate can demonstrate 30-40% CR rate and +30% 12-month survival. The DMC reviews Stage-1 data after 50 experimental arm patients can be compared to 50 in the LDAC SOC comparator arm and will look at both CR rate and 12-month survival rate. Vosaroxin's LI-1 updates in early 3Q13 Arm-3 (monotherapy) and 4Q13 Arm-4 (combo with LDAC) could be major catalysts driving us to include meaningful FL revenues in our model. While it is risky to predict Phase III results based on Phase II data, we are at least encouraged that the previous FL Phase II REVEAL-1 Vosaroxin monotherapy trial (non-randomized) demonstrated a 31% CR rate (combined CR+CRp rate 35%) and a 38% 12-month survival rate. Interim data from MD Anderson's IST in MDS is important to Sunesis as it will provide the first look at combining vosaroxin with a hypomethylating agent such as Decitabine. While the primary end point of this trial will evaluate maximum tolerated doses (MTD) of the combination, it should also provide emerging efficacy details characterizing vosaroxin's potential as an MDS therapeutic option. Given that we
currently do not include any MDS revenues in our model, this trial could begin to de-risk MDS as a potential future growth opportunity for Vosaroxin
Current assets of discontinued operations, held for sale 175,950,575 144,751,290
I think the commas are further to the right than they should be - there is no way their assets are going to be worth anywhere near that & the company should back up the valuation they are claiming on these held assets.
That's said, there's no point in selling this currently near-worthless stock except to take a loss, which can be done at $0.395 or $0
I'm certainly not going to buy any more shares and wouldn't advise anyone else I knew to buy, but I don't see much point in selling at this point. Sometimes crazy #$%$ happens.
Based on yesterdays press release from the company, it looks like the company should have news on an extensive survey in about 3-4 months
The trading volume for this small company is kind of silly, and yes some pump and dump newsletters picked up on this stock, but graphite prices are good and I think there is some potential here, especially if the results of the survey are positive. I don't own a lot of this stock, but I feel comfortable ignoring the drastic swings for now and waiting for real value.
Anyone here actually hold this stock on its merits?
In October of last year, you said ATP Oil & Gas was a strong by at $6.00 a share. Your predictions were a little off mark.. Last I checked it was trading at $0.13 a share.
At any rate, congratulations on your two degrees in science. Next time you start a thread, maybe you could post some useful/insightful perspective? I'm curious, for example, whether or not SNSS's AML treatment might have benefit to those with MDS (Myelodysplastic syndrome), but I don't know enough about the underlying pathology to know if this is a possibility. I have no degrees in science, just an interest in putting some of my meager investment money into a company that is trying to do some good for people with terminal illnesses.
mining_phd - If you have some actual useful information regarding SNSS or at all relevant to my post, please share. Otherwise stop pumping other stocks here.
In October of last year, you said ATP Oil & Gas was a strong by at $6.00 a share. It was definitely a big mover -- down to $0.13 a little over a year later.
I'll stick to SNSS.. I like my 200% return so far, but I like the stock, the company, and what they are trying to do enough to hang in there until they bring it to market.
In my view, nothing about this stock, company, or drug has changed since August. For those that bought intending to hold until their drug is brought to market, nothing has changed other than fluctuations in share price. Correct me if I'm wrong please.
Anyone familiar with the science, would be interested in your thoughts on whether this drug could potentially be useful in treating mds aka pre-leukemia aka pre-AML? prevelence of MDS is twice AML and currently the only treatment is aronesp type drugs.. Much bigger market .. Seems like it would be worth a clinical trial at some point.
Takes a lot of balls to short this stock ahead of the interim analysis.. Shorts are going to be covering & short volume should decrease as we get closer to the interim analysis. Peer review paper doesn't have much in the way of new news, but no negative surprises.. I've been long over a year on this stock and am expecting a decent profit by this time next year. Enough volatility still for short term traders, but I think this is still a good long term buy under $4-5/share.
Ugh if you don't understand BASIC p&l concepts, do yourself a favor and put your money in a bank earning 0.2%
The only way they are going to make money on $17mil in inventory is to sell it for substantially more than $17mil.
This company is giving away their product. They have no price leverage.. Either they boost the sales of their own handsets ASAP or somehow reach economy of scale that allows them to eek out some margin.
The expense of inventory (Cost of goods sold) is not realized/booked until it is sold (unless it is written off as overstock/obsolete). So yes, you can ignore 17mil in inventory -- its all about their margins right now.. They can grow the top line like mad, but if they are not making anything on a phone, this stock is going to continue to drop. If they did reach better economies of scale this quarter and no negative surprises, I would expect a big bounce. Not holding my breath though.
They purchased them on Oct 11th, BEFORE the price tanked at $67+ a share.
I'd feel a little better about ESI if they were snapping up shares at today's prices. I think ESI is a decent value, but I wouldn't buy them because of anything Blum Capital did before the stock tanked.
"Gross profit for the retail segment, which includes distribution, occupancy and merchandising costs was 16.5% compared to 22.1% in the prior year period. The decrease in gross profit was driven by lower merchandise margins and the deleveraging of occupancy costs."... (from this mornings earnings release)
Yikes that's -5.6 points or a drop of 25% over q2 of 2009, which was a terrible quarter itself..
Does anyone know what their average remaining lease terms are on their retail stores? Any room to cut costs here soon or are they going to keep burning through money like this?
If the partnership triggers a change of control (I.e. Acquired) and the proceeds are less than $45m, common shareholders get nothing.
In 2001 they executed well with the 70's / hippie style stuff. By '05, hippie stuff was on it's way out.. by 2007, 80's influences were big.. DLIA's went from trendy to just blah.
You can get the 12-19 market while picking up the 18-30..
Their brand is worthless, as evidenced by their willingness to hawk it selling ad space.
I'm suggesting they ditch the name, relaunch with a new line and go with either a distinct style, or embrace retro in a big way like http://www.modcloth.com has.
Blowing a few million on this now is still possible. If their game is to just wait for a macro recovery they're going to get crushed and just burn through the rest of their cash.
I like this stock because of the cash on hand. I'm hopeful that they realize they can't keep doing what they're doing today and will make a change. I keep coming back to the fact that they're selling ad space on their website though. Why the heck would they do this?? Their marketing folks need to go.
First, take the ads for other companies off of your website. This is an obvious acknowledgement that your brand is worth nothing as you're willing to run other companies ads for video games on your front page. Absurd.
Second, the brand is dead, the clothing line is cheap and style is no better than wal-mart - DLIA's has a chunk of cash, use it - acquire a hip private that knows how to build customer loyalty & run a real web presence -- top on my list would be small privately held modcloth.com.
Third, target 16-30, not 12-16. Your stuff is cheap and undifferentiated.. The younger market buying cheap stuff is going to do so at Wal-Mart, Target, etc.. the yuppie kids are buying A&F, Gap, etc. Need a different style with higher price points appealing to a broader market with more control over their own wallets.
Look at amazon's reviews for older generation cable modems. Zoom hardly has any at all compared to other brands. I'm not sure why someone who is savvy enough to buy their own cable modem rather than use the one provided by their internet company would choose Zoom products over Motorola, LinkSys, and other leading brands.
I would expect any major revenue to come from a large OEM deal.
I've had sell orders in for some time at around $.40 with schwab - can anyone explain why I keep seeing buys above this? Maybe something funky with .ob, I don't know.. I guess I could call schwab, but if anyone has any insight please let me know. Otherwise I'll give schwab a ring & share what they say.